Expression of human E46K-mutated α-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment

Experimental Neurology

Volumn 240, Issue 1, 2013, Pages 44-56

  Cannon, Jason R ^a,b   Geghman, Kindiya D ^c   Tapias, Victor ^b   Sew, Thomas ^b   Dail, Michelle K ^b   Li, Chenjian ^d   Greenamyre, J Timothy ^b  

^a PURDUE UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Alpha synuclein; BAC transgenic; E46K; Parkinson's disease; Rotenone

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; MUTANT PROTEIN; ROTENONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; BRAIN DAMAGE; CATECHOLAMINE METABOLISM; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; GENE MUTATION; GENETIC PREDISPOSITION; GENOTYPE; MITOCHONDRIAL TOXICITY; NEUROMODULATION; NEUROPATHOLOGY; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RISK FACTOR;

ALPHA-SYNUCLEIN; ANIMALS; CHROMOSOMES, ARTIFICIAL, BACTERIAL; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; MITOCHONDRIA; PARKINSONIAN DISORDERS; PREGNANCY; RATS; RATS, TRANSGENIC; ROTENONE;

EID: 84870871828     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2012.11.007     Document Type: Article

References (54)

1. Adams J.R., van Netten H., Schulzer M., Mak E., McKenzie J., Strongosky A., Sossi V., Ruth T.J., Lee C.S., Farrer M., Gasser T., Uitti R.J., Calne D.B., Wszolek Z.K., Stoessl A.J. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 2005, 128:2777-2785.
2. Bekris L.M., Mata I.F., Zabetian C.P. The genetics of Parkinson disease. J. Geriatr. Psychiatry Neurol. 2010, 23:228-242.
3. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 2000, 3:1301-1306.
4. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
5. Braak H., Ghebremedhin E., Rub U., Bratzke H., Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004, 318:121-134.
6. Cannon J.R., Greenamyre J.T. Neurotoxic in vivo models of Parkinson's disease recent advances. Prog. Brain Res. 2010, 184:17-33.
7. Cannon J.R., Tapias V., Na H.M., Honick A.S., Drolet R.E., Greenamyre J.T. A highly reproducible rotenone model of Parkinson's disease. Neurobiol. Dis. 2009, 34:279-290.
8. Cannon J.R., Sew T., Montero L., Burton E.A., Greenamyre J.T. Pseudotype-dependent lentiviral transduction of astrocytes or neurons in the rat substantia nigra. Exp. Neurol. 2011, 228:41-52.
9. Chandran J.S., Lin X., Zapata A., Hoke A., Shimoji M., Moore S.O., Galloway M.P., Laird F.M., Wong P.C., Price D.L., Bailey K.R., Crawley J.N., Shippenberg T., Cai H. Progressive behavioral deficits in DJ-1-deficient mice are associated with normal nigrostriatal function. Neurobiol. Dis. 2008, 29:505-514.
10. Chesselet M.F., Richter F. Modelling of Parkinson's disease in mice. Lancet Neurol. 2011, 10:1108-1118.
11. Choi W., Zibaee S., Jakes R., Serpell L.C., Davletov B., Crowther R.A., Goedert M. Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein. FEBS Lett. 2004, 576:363-368.
12. Emmer K.L., Waxman E.A., Covy J.P., Giasson B.I. E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment. J. Biol. Chem. 2011, 286:35104-35118.
13. Filipiak W.E., Saunders T.L. Advances in transgenic rat production. Transgenic Res. 2006, 15:673-686.
14. Fleming S.M., Chesselet M.F. Behavioral phenotypes and pharmacology in genetic mouse models of Parkinsonism. Behav. Pharmacol. 2006, 17:383-391.
15. Fleming S.M., Schallert T., Ciucci M.R. Cranial and related sensorimotor impairments in rodent models of Parkinson's disease. Behav. Brain Res. 2012, 231:317-322.
16. Forno L.S. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 1996, 55:259-272.
17. Giasson B.I., Duda J.E., Quinn S.M., Zhang B., Trojanowski J.Q., Lee V.M. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 2002, 34:521-533.
18. Glasl L., Kloos K., Giesert F., Roethig A., Di Benedetto B., Kuhn R., Zhang J., Hafen U., Zerle J., Hofmann A., de Angelis M.H., Winklhofer K.F., Holter S.M., Vogt Weisenhorn D.M., Wurst W. Pink1-deficiency in mice impairs gait, olfaction and serotonergic innervation of the olfactory bulb. Exp. Neurol. 2012, 235:214-227.
19. Goerendt I.K., Messa C., Lawrence A.D., Grasby P.M., Piccini P., Brooks D.J. Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study. Brain 2003, 126:312-325.
20. Goldberg M.S., Fleming S.M., Palacino J.J., Cepeda C., Lam H.A., Bhatnagar A., Meloni E.G., Wu N., Ackerson L.C., Klapstein G.J., Gajendiran M., Roth B.L., Chesselet M.F., Maidment N.T., Levine M.S., Shen J. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J. Biol. Chem. 2003, 278:43628-43635.
21. Goldberg M.S., Pisani A., Haburcak M., Vortherms T.A., Kitada T., Costa C., Tong Y., Martella G., Tscherter A., Martins A., Bernardi G., Roth B.L., Pothos E.N., Calabresi P., Shen J. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 2005, 45:489-496.
22. Gong S., Yang X.W., Li C., Heintz N. Highly efficient modification of bacterial artificial chromosomes (BACs) using novel shuttle vectors containing the R6Kgamma origin of replication. Genome Res. 2002, 12:1992-1998.
23. Guttman M., Boileau I., Warsh J., Saint-Cyr J.A., Ginovart N., McCluskey T., Houle S., Wilson A., Mundo E., Rusjan P., Meyer J., Kish S.J. Brain serotonin transporter binding in non-depressed patients with Parkinson's disease. Eur. J. Neurol. 2007, 14:523-528.
24. Itier J.M., Ibanez P., Mena M.A., Abbas N., Cohen-Salmon C., Bohme G.A., Laville M., Pratt J., Corti O., Pradier L., Ret G., Joubert C., Periquet M., Araujo F., Negroni J., Casarejos M.J., Canals S., Solano R., Serrano A., Gallego E., Sanchez M., Denefle P., Benavides J., Tremp G., Rooney T.A., Brice A., Garcia de Yebenes J. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum. Mol. Genet. 2003, 12:2277-2291.
25. Kitada T., Pisani A., Porter D.R., Yamaguchi H., Tscherter A., Martella G., Bonsi P., Zhang C., Pothos E.N., Shen J. Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:11441-11446.
26. Kitada T., Pisani A., Karouani M., Haburcak M., Martella G., Tscherter A., Platania P., Wu B., Pothos E.N., Shen J. Impaired dopamine release and synaptic plasticity in the striatum of parkin-/- mice. J. Neurochem. 2009, 110:613-621.
27. Lee M.K., Stirling W., Xu Y., Xu X., Qui D., Mandir A.S., Dawson T.M., Copeland N.G., Jenkins N.A., Price D.L. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:8968-8973.
28. Litvan I., Bhatia K.P., Burn D.J., Goetz C.G., Lang A.E., McKeith I., Quinn N., Sethi K.D., Shults C., Wenning G.K. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov. Disord. 2003, 18:467-486.
29. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
30. Manning-Bog A.B., Caudle W.M., Perez X.A., Reaney S.H., Paletzki R., Isla M.Z., Chou V.P., McCormack A.L., Miller G.W., Langston J.W., Gerfen C.R., Dimonte D.A. Increased vulnerability of nigrostriatal terminals in DJ-1-deficient mice is mediated by the dopamine transporter. Neurobiol. Dis. 2007, 27:141-150.
31. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A., Mucke L. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 2000, 287:1265-1269.
32. McLean J.R., Hallett P.J., Cooper O., Stanley M., Isacson O. Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression. Mol. Cell. Neurosci. 2012, 49:230-239.
33. Metcalf W.W., Jiang W., Daniels L.L., Kim S.K., Haldimann A., Wanner B.L. Conditionally replicative and conjugative plasmids carrying lacZ alpha for cloning, mutagenesis, and allele replacement in bacteria. Plasmid 1996, 35:1-13.
34. Nandhagopal R., Mak E., Schulzer M., McKenzie J., McCormick S., Sossi V., Ruth T.J., Strongosky A., Farrer M.J., Wszolek Z.K., Stoessl A.J. Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study. Neurology 2008, 71:1790-1795.
35. Perez F.A., Curtis W.R., Palmiter R.D. Parkin-deficient mice are not more sensitive to 6-hydroxydopamine or methamphetamine neurotoxicity. BMC Neurosci. 2005, 6:71.
36. Politis M., Loane C. Serotonergic dysfunction in Parkinson's disease and its relevance to disability. ScientificWorldJournal 2011, 11:1726-1734.
37. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
38. Richfield E.K., Thiruchelvam M.J., Cory-Slechta D.A., Wuertzer C., Gainetdinov R.R., Caron M.G., Di Monte D.A., Federoff H.J. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp. Neurol. 2002, 175:35-48.
39. Schwarting R.K., Huston J.P. Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae. Prog. Neurobiol. 1996, 49:215-266.
40. Shizuya H., Birren B., Kim U.J., Mancino V., Slepak T., Tachiiri Y., Simon M. Cloning and stable maintenance of 300-kilobase-pair fragments of human DNA in Escherichia coli using an F-factor-based vector. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:8794-8797.
41. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M.R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., Gwinn-Hardy K. Alpha-synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
42. Smith G.A., Isacson O., Dunnett S.B. The search for genetic mouse models of prodromal Parkinson's disease. Exp. Neurol. 2012, 237:267-273.
43. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
44. Strafella A.P., Ko J.H., Grant J., Fraraccio M., Monchi O. Corticostriatal functional interactions in Parkinson's disease: a rTMS/[11C]raclopride PET study. Eur. J. Neurosci. 2005, 22:2946-2952.
45. Tanner C.M., Kamel F., Ross G.W., Hoppin J.A., Goldman S.M., Korell M., Marras C., Bhudhikanok G.S., Kasten M., Chade A.R., Comyns K., Richards M.B., Meng C., Priestley B., Fernandez H.H., Cambi F., Umbach D.M., Blair A., Sandler D.P., Langston J.W. Rotenone, paraquat, and Parkinson's disease. Environ. Health Perspect. 2011, 119:866-872.
46. Tapias V., Cannon J.R., Greenamyre J.T. Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model. J. Neurosci. Res. 2010, 88:420-427.
47. Von Coelln R., Thomas B., Savitt J.M., Lim K.L., Sasaki M., Hess E.J., Dawson V.L., Dawson T.M. Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:10744-10749.
48. Welchko R.M., Leveque X.T., Dunbar G.L. Genetic rat models of Parkinson's disease. Park. Dis. 2012, 2012:128356.
49. Whishaw I.Q., Kolb B. The Behavior of the Laboratory Rat: A Handbook with Tests 2004, Oxford University Press, Oxford.
50. Yamaguchi H., Shen J. Absence of dopaminergic neuronal degeneration and oxidative damage in aged DJ-1-deficient mice. Mol. Neurodegener. 2007, 2:10.
51. Yang X.W., Gong S. An overview on the generation of BAC transgenic mice for neuroscience research. Curr. Protoc. Neurosci. (Suppl. 21) 2005, 5.20.1-5.20.11. (Chapter 5, Unit 5 20).
52. Yavich L., Oksman M., Tanila H., Kerokoski P., Hiltunen M., van Groen T., Puolivali J., Mannisto P.T., Garcia-Horsman A., MacDonald E., Beyreuther K., Hartmann T., Jakala P. Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human alpha-synuclein. Neurobiol. Dis. 2005, 20:303-313.
53. Zarranz J.J., Alegre J., Gomez-Esteban J.C., Lezcano E., Ros R., Ampuero I., Vidal L., Hoenicka J., Rodriguez O., Atares B., Llorens V., Gomez Tortosa E., del Ser T., Munoz D.G., de Yebenes J.G. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004, 55:164-173.
54. Zhou H., Huang C., Tong J., Hong W.C., Liu Y.J., Xia X.G. Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake. Int. J. Biol. Sci. 2011, 7:753-761.